Nexalin Technology (NASDAQ:NXL – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.28) EPS for the quarter, Zacks reports. The business had revenue of $0.03 million during the quarter. Nexalin Technology had a negative net margin of 3,407.98% and a negative return on equity of 187.59%.
Nexalin Technology Stock Up 10.3 %
Shares of NASDAQ:NXL opened at $2.15 on Friday. The stock has a market cap of $28.60 million, a price-to-earnings ratio of -3.36 and a beta of 4.33. The firm’s 50 day moving average price is $2.85 and its 200 day moving average price is $2.47. Nexalin Technology has a fifty-two week low of $0.35 and a fifty-two week high of $4.49.
Analysts Set New Price Targets
Separately, Maxim Group reiterated a “hold” rating on shares of Nexalin Technology in a research report on Thursday, December 5th.
About Nexalin Technology
Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.
Further Reading
- Five stocks we like better than Nexalin Technology
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Investing in Construction Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- 3 REITs to Buy and Hold for the Long Term
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
